Compounds / Prostamax
Prostamax
Also known as: KEDP; Lys-Glu-Asp-Pro; KEDP tetrapeptide; Khavinson prostate bioregulator; CAS 473578-47-1
Primary research focus: Prostate tissue research (Khavinson short-peptide bioregulator)
Last updated July 2026 · Reviewed against FDA labeling and published research.
What is Prostamax?
Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro, or KEDP) from the Khavinson family of short-peptide bioregulators, conceived as the defined-sequence successor to older bovine prostate extracts (Prostatilen, marketed in Russia as Vitaprost). It is studied preclinically for prostate inflammation and age-related prostate change. An important caveat: most of the actual clinical prostate evidence belongs to the parent extract, not to the synthetic peptide. It is a research compound with no FDA approval.
Khavinson short peptides are proposed to cross cell and nuclear membranes and bind specific DNA sequences, modulating tissue-specific gene expression rather than acting through cell-surface receptors. For Prostamax, the proposed activity is in prostate epithelium, shifting gene expression toward a less inflamed, less age-degraded state. Reported laboratory findings include chromatin effects measured by differential scanning calorimetry in human lymphocytes, increased sister chromatid exchange frequency, changes in nucleolus organizer region activity, and decondensation of pericentromeric heterochromatin. This mechanism is class-level, derives from the originating program, and has limited independent Western replication; treat it as proposed rather than established.
How it’s supplied
Not an FDA-approved or commercially manufactured medicine. It is sold as a research-grade lyophilized powder (commonly 20 mg vials) for reconstitution, and in some markets as oral capsules. Research-grade products are not FDA-reviewed for potency or sterility, and product labeling is not standardized across vendors.
Dosage Chart
Units shown are for a U-100 insulin syringe (100 units = 1 mL), calculated from the vial size and BAC water you select. Always confirm against your prescription and your syringe markings.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Weeks 1-2 | 500mcg 1x Daily | — | |
| Weeks 3-4 | 750mcg | 1x Daily | — |
| Weeks 5-12 | 1mg | 1x Daily | — |
- Rotate injection sites to reduce irritation and lipohypertrophy
- Not for use during pregnancy or breastfeeding
- Do not exceed the recommended dose to try to speed results
Potential Benefits and Side Effects
Effects reported in published research. Not a promise of results, and not medical advice.
- Reported in preclinical research within the Khavinson tradition; not established in Western controlled trials, and not to be confused with the parent extract's clinical record.
- Reported anti-inflammatory and tissue-protective effects in rat chronic prostatitis models.
- Reported slowing of pathological prostate remodeling in animal models.
- Reported chromatin decondensation and gene-expression effects in lymphocyte and prostate cell cultures.
- Proposed tissue-selective bioregulation of prostatic epithelial homeostasis.
- No robust human adverse-effect data are available for the synthetic peptide.
- The Khavinson short-peptide class is reported to have a clean safety profile in Russian use, but this is not established by Western trials for Prostamax specifically.
- Human tolerability and long-term safety are unknown.
Warnings and contraindications
Important safety information. This is not exhaustive — read the full prescribing information and consult your prescriber or pharmacist.
- No FDA-approved labeling exists; the following reflect the compound's status and the limits of its evidence, not established label warnings.
- There are no Western randomized controlled trials of synthetic KEDP, and no independent replication of its specific effects outside the originating institute.
- The clinical track record of the parent bovine prostate extract (Prostatilen/Vitaprost) does not automatically transfer to the synthetic peptide; these are different products.
- Prostate symptoms can reflect serious conditions including cancer; anyone with urinary symptoms or prostate concerns should be evaluated by a clinician rather than self-treating with a research compound.
- The name is not standardized: some sellers label different sequences, and an unrelated prostate supplement is also sold as Prostamax.
- Research-grade material varies in identity and purity.
- Not established; no FDA-approved labeling. Precautionary considerations include known hypersensitivity to the peptide, and prostate symptoms warranting medical evaluation rather than self-directed use.
Reconstitution Steps
How to prepare the lyophilized vial. Confirm specifics with your pharmacist or prescriber.
- Confirm the amount of peptide in the vial and the volume of diluent you intend to use before starting.
- Wash your hands and gather supplies: the lyophilized vial, the diluent (typically bacteriostatic water), an alcohol swab, and a sterile syringe.
- Let the vial and diluent reach room temperature if they were refrigerated or frozen.
- Wipe the rubber stopper of both the peptide vial and the diluent vial with a fresh alcohol swab and let them air dry.
- Draw the intended diluent volume into the syringe.
- Insert the needle into the vial and slowly release the diluent down the inside wall rather than directly onto the powder, to avoid foaming.
- Do not shake. Gently swirl or roll the vial until fully dissolved.
- Inspect the solution: it should be clear and colorless with no visible particles. Do not use if cloudy or containing particles.
- Note the resulting concentration (amount divided by diluent volume) so it matches the reconstitution calculator on this page.
- Label the vial with the reconstitution date and store as directed under reconstituted storage.
US regulatory status
Classifications are public record but can change. For reference only, not legal advice.
Development: Prostamax is the prostate-directed member of the Khavinson short-peptide bioregulator family from the St. Petersburg Institute of Bioregulation and Gerontology. Its lineage matters for reading the evidence: the bovine prostate extract Prostatilen (sold in Russia as Vitaprost) carries the bulk of the human clinical literature for chronic prostatitis and benign prostatic conditions, while the synthetic single-sequence KEDP peptide has far less data of its own, consisting mostly of Khavinson-school animal and cell-culture work reporting reduced prostate inflammation and slowed pathological remodeling in rat prostatitis models. The chromatin and gene-expression claims rest on the broader Khavinson framework rather than direct human prostate trials. There is no FDA or EMA approval, no public IND, and no registered Western clinical trial.
Notes: Prostamax is not FDA-approved and has no recognized clinical use in the US. It is not on the FDA 503A bulk drug substances list and has no approval or shortage basis for compounding, so it is not eligible for 503A or 503B compounding. It is sold as a research-grade chemical; such products are not FDA-reviewed for safety, potency, or sterility. It is not a controlled substance.
International status
Pharmacokinetics
Storage and handling
Important Notes
Practical considerations for consistency and safety.
- The clinical evidence people cite for Prostamax mostly belongs to the parent bovine extract (Prostatilen/Vitaprost), not to the synthetic KEDP peptide; the two are not interchangeable.
- The name is ambiguous: an unrelated prostate supplement is also sold as Prostamax, and some vendors label different sequences with the same name. Verify against the certificate of analysis.
- There are no Western randomized controlled trials and no independent replication outside the originating institute.
- Prostate symptoms warrant clinical evaluation; they can reflect serious conditions including cancer.
- It is distinct from Livagen (KEDA), with which it shares the KED core.
Lifestyle Factors
- Khavinson bioregulators are typically studied in short cyclic courses rather than continuous daily use.
- Human lifestyle interactions are unstudied for Prostamax.
References
Related compounds
Important disclaimer
This page is an educational reference, not medical advice, a diagnosis, or a treatment recommendation, and not a substitute for your prescriber or pharmacist. Approval and regulatory status varies by compound and can change. Always confirm against current prescribing information and consult a qualified healthcare professional before making any decision about a medication.